These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 26831183)

  • 1. Prostate cancer: Personalized risk - stratified screening or abandoning it altogether?
    Carlsson SV; Kattan MW
    Nat Rev Clin Oncol; 2016 Mar; 13(3):140-2. PubMed ID: 26831183
    [No Abstract]   [Full Text] [Related]  

  • 2. Early detection of prostate cancer: European Association of Urology recommendation.
    Heidenreich A; Abrahamsson PA; Artibani W; Catto J; Montorsi F; Van Poppel H; Wirth M; Mottet N;
    Eur Urol; 2013 Sep; 64(3):347-54. PubMed ID: 23856038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate-specific antigen or human kallikrein 3? Recent developments.
    Diamandis EP
    Tumour Biol; 1998; 19(2):65-7; discussion 67-8. PubMed ID: 9486557
    [No Abstract]   [Full Text] [Related]  

  • 4. Controversy of the prostate-specific antigen test era: should prostate cancer be detected and treated in all patients?
    Zhang N; Zhang XD
    Chin Med J (Engl); 2013; 126(15):2803-4. PubMed ID: 23924445
    [No Abstract]   [Full Text] [Related]  

  • 5. Value of a Statistical Model Based on Four Kallikrein Markers in Blood, Commercially Available as 4Kscore, in All Reasonable Prostate Biopsy Subgroups.
    Vickers AJ; Vertosick EA; Sjoberg DD
    Eur Urol; 2018 Oct; 74(4):535-536. PubMed ID: 29903434
    [No Abstract]   [Full Text] [Related]  

  • 6. The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential.
    Ström P; Nordström T; Aly M; Egevad L; Grönberg H; Eklund M
    Eur Urol; 2018 Aug; 74(2):204-210. PubMed ID: 29331214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accuracy of Prostate-Specific Antigen Values in Prostate Cancer Registries.
    Mittakanti HR; Thomas IC; Shelton JB; Makarov DV; Skolarus TA; Cooperberg MR; Chung BI; Sonn GA; Brooks JD; Leppert JT
    J Clin Oncol; 2016 Oct; 34(29):3586-3587. PubMed ID: 27458297
    [No Abstract]   [Full Text] [Related]  

  • 8. Percent free prostate-specific antigen for first-time prostate biopsy.
    Lee CT; Scardino PT
    Urology; 2001 Apr; 57(4):594-8. PubMed ID: 11306355
    [No Abstract]   [Full Text] [Related]  

  • 9. Should we screen for prostate cancer? A re-examination of the evidence.
    Del Mar CB; Glasziou PP; Hirst GH; Wright RG; Hoffmann TC
    Med J Aust; 2013 Jun; 198(10):525-7. PubMed ID: 23725255
    [No Abstract]   [Full Text] [Related]  

  • 10. Risk assessment models to evaluate the necessity of prostate biopsies in North Chinese patients with 4-50 ng/mL PSA.
    Zhao J; Liu S; Gao D; Ding S; Niu Z; Zhang H; Huang Z; Qiu J; Li Q; Li N; Xie F; Cui J; Lu J
    Oncotarget; 2017 Feb; 8(6):9935-9946. PubMed ID: 28039477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening for prostate cancer: prostate-specific antigen testing is not effective.
    Hitzeman N; Molina M
    Am Fam Physician; 2011 Apr; 83(7):802-4. PubMed ID: 21524045
    [No Abstract]   [Full Text] [Related]  

  • 12. What is a "Diagnostic Test Reference Range" Good for?
    Habibzadeh P; Yadollahie M; Habibzadeh F
    Eur Urol; 2017 Nov; 72(5):859-860. PubMed ID: 28558944
    [No Abstract]   [Full Text] [Related]  

  • 13. Prostate Cancer Screening and the Goldilocks Principle: How Much Is Just Right?
    Faiena I; Holden S; Cooperberg MR; Holden S; Soule HR; Simons JW; Morgan TM; Penson DF; Morgans AK; Hussain M
    J Clin Oncol; 2018 Apr; 36(10):937-941. PubMed ID: 29401003
    [No Abstract]   [Full Text] [Related]  

  • 14. Addressing overtreatment following the diagnosis of localized prostate cancer.
    Tawadros T; Valerio M
    Expert Rev Anticancer Ther; 2016; 16(4):373-4. PubMed ID: 26776104
    [No Abstract]   [Full Text] [Related]  

  • 15. Beyond PSA: The Role of Prostate Health Index (phi).
    Ferro M; De Cobelli O; Lucarelli G; Porreca A; Busetto GM; Cantiello F; Damiano R; Autorino R; Musi G; Vartolomei MD; Muto M; Terracciano D
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32053990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Redefining the Clinical States of Prostate Cancer in the Modern Era.
    McKay R
    Oncology (Williston Park); 2021 Apr; 35(4):169. PubMed ID: 33877748
    [No Abstract]   [Full Text] [Related]  

  • 17. The New US Preventive Services Task Force "C" Draft Recommendation for Prostate Cancer Screening.
    Cooperberg MR
    Eur Urol; 2017 Sep; 72(3):326-328. PubMed ID: 28535948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful separation between benign prostatic hyperplasia and prostate cancer by measurement of free and complexed PSA.
    Lilja H; Stenman UH
    Cancer Treat Res; 1996; 88():93-101. PubMed ID: 9239474
    [No Abstract]   [Full Text] [Related]  

  • 19. The utility of PSA doubling time to monitor prostate cancer recurrence.
    Wieder JA; Belldegrun AS
    Mayo Clin Proc; 2001 Jun; 76(6):571-2. PubMed ID: 11393493
    [No Abstract]   [Full Text] [Related]  

  • 20. Managing localized prostate cancer in the era of prostate-specific antigen screening.
    Brooks JD
    Cancer; 2013 Nov; 119(22):3906-9. PubMed ID: 24006273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.